A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Redox and Curative Partner to Connect COVID-19 Test Results to Public Health Departments

Patient Data Integration Helps Inform Policies for Contact Tracing and Phased Openings

Redox, Inc., the leading interoperability platform for healthcare data exchange, is working with FDA-authorized COVID-19 testing company Curative to safely connect patient data to state public health departments for notification of results.

Redox notes since formalizing the partnership in May, the duo has kicked off projects with 24 states, with two, Illinois and Delaware, now fully live.

Other COVID-19 tests, such as the nasal swab and oral-based approach, are difficult for consumers to handle, are hard to administer en masse, or may pose a risk of exposure for healthcare workers. Curative offers an easy to use, accurate, and rapidly scalable oral fluid-based testing method that is less invasive, and which distributes results within just 48 hours. Using its connection with Redox, Curative immediately sends test results to state officials for reporting, contact tracing programs, and to inform policies as regions move through phases for opening the economy.

“Every state has its own unique, mandatory reporting requirements for COVID-19 testing. This can be challenging for an organization like ours, which is so focused on working as quickly as possible to scale up testing services nationwide,” said Isaac Turner, CIO and co-founder, Curative. “Redox has given us a secure and scalable integration strategy to quickly automate this reporting requirement across all the different systems we need to work with. Redox allows us to be confident that this critical data will get to the right destination, in the proper format, and in a timely manner, so we can continue to focus on scaling out COVID-19 testing across the nation.”

Redox standardizes healthcare data with a vendor-agnostic application programming interface (API) and a cloud network where organizations can exchange information. This networked approach to interoperability simplifies the way organizations exchange healthcare data by normalizing data formats and eliminating redundant connections. In this novel use case, Curative utilizes the Redox API to allow for a secure, efficient flow of data between it and public health authorities, further extending Redox’s network of more than 700 healthcare delivery organizations to include state public health agencies and regional HIEs.

“As we start to safely reopen the economy, state officials must have an accurate and efficient testing and contact tracing system,” said Niko Skievaski, co-founder and president of Redox. “Curative’s simpler, safer process has taken testing to a new level, and together with Redox, we’ll help to not only control the spread of the disease but also be better able to allocate healthcare resources appropriately. We hope this will become a core piece of public health infrastructure.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy